MRNA (Moderna) Stock Analysis - Analyst Ratings

Moderna (MRNA) is a publicly traded Healthcare sector company. As of May 20, 2026, MRNA trades at $48.28 with a market cap of $19.09B and a P/E ratio of -5.92. MRNA moved +5.33% today. Year to date, MRNA is +48.15%; over the trailing twelve months it is +73.25%. Its 52-week range spans $22.28 to $67.96. Analyst consensus is neutral with an average price target of $44.73. Rallies surfaces MRNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate MRNA?

15 analysts cover MRNA: 0 strong buy, 1 buy, 13 hold, 1 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $44.73.

MRNA Key Metrics

Key financial metrics for MRNA
MetricValue
Price$48.28
Market Cap$19.09B
P/E Ratio-5.92
EPS$-8.15
Dividend Yield0.00%
52-Week High$67.96
52-Week Low$22.28
Volume3.87M
Avg Volume0
Revenue (TTM)$2.23B
Net Income$-3.19B
Gross Margin22.11%

MRNA Analyst Consensus

15 analysts cover MRNA: 0 strong buy, 1 buy, 13 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.73.

Latest MRNA News

Recent MRNA Insider Trades

  • Hoge Stephen sold 53.34K (~$2.58M) on May 15, 2026.
  • Hussain Abbas sold 5.68K (~$264.95K) on May 1, 2026.
  • Klinger Shannon Thyme sold 13.88K (~$726.05K) on Mar 2, 2026.

Common questions about MRNA

What do analysts rate MRNA?
15 analysts cover MRNA: 0 strong buy, 1 buy, 13 hold, 1 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $44.73.
Does Rallies show MRNA price targets?
Yes. Rallies tracks MRNA analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is MRNA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for MRNA. It does not provide personalized investment advice.
MRNA

Moderna